← Leaderboards
Utthara Nayar
Johns Hopkins University
$738,873
Attributed
$738,873
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $195.2K · FY2021–24$200K$150K$100K$50K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$738,873 · 2
By mechanism
K22$575,123 · 1
R03$163,750 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Anirban Maitra$50,247,714
- Jeremy Goecks$11,144,983
- Richard J Jones$17,555,212
- Patricia D. Hurn$12,295,669
- Lydia Pecker$1,946,939
Others in their field
Other Emerging Leaders on “Mouse Model”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$13,186,126
- Nuno Macarico Da Costa · Allen Institute$11,726,937
- Forrest Christie Collman · Allen Institute$11,726,937
- Jacqueline K White · Jackson Laboratory$11,670,339
- Thomas Dick · Rbhs-New Jersey Medical School$11,611,284
Research focus
Mouse ModelPrecision MedicineGenetic TranscriptionMortalityMutantPositioning AttributeEndocrineEstrogen ReceptorsIncidenceMetastatic Breast CancerAtac-SeqBiologyMutationOrganoidsEffectivenessCancer TherapyEstrogen AntagonistsEstrogen Receptor PositiveCell LineGrantIndividualized MedicineMalignant Breast NeoplasmClinicResistance
Grant awards (4)
Novel estrogen receptor mutations as a biomarker dictating therapy response in advanced endocrine-resistant estrogen receptor-positive breast cancer$163,750
R03 · FY2024 · CA · contact PI
Investigating the biology and therapeutic vulnerabilities of ER+ metastatic breast cancer with activating HER2 mutations$188,889
K22 · FY2023 · CA · contact PI
Investigating the biology and therapeutic vulnerabilities of ER+ metastatic breast cancer with activating HER2 mutations$191,014
K22 · FY2022 · CA · contact PI
Investigating the biology and therapeutic vulnerabilities of ER+ metastatic breast cancer with activating HER2 mutations$195,220
K22 · FY2021 · CA · contact PI